Clinical Development 

ATS907 is a novel ROCK inhibitor that has entered into clinical evaluation in patients in the United States.  The first in human study is a two-stage, randomized, investigator-masked, dose-ranging, safety and efficacy study in subjects with primary open angle glaucoma and or ocular hypertension.  This study is intended to evaluate a number of different concentrations of ATS907 ophthalmic formulation and to provide preliminary information on safety, tolerability, and efficacy (reduction in IOP). For more information on the clinical studies please see www.clinicaltrials.gov . Altheos expects to initiate the second stage of this trial, a comparison of ATS907 and latanoprost, a prostaglandin agonist, shortly following completion of the first stage.